Medical device sales boost Covidien; dollar drags down forecast
This article was originally published in Clinica
Executive Summary
Despite making strong revenue growth in its medical devices business, Covidien cut its financial outlook for 2009 due to the negative impact of the strengthening US dollar. The Hamilton, Bermuda-based firm said that it expected sales in fiscal 2009 to grow to a maximum of 3%, down from its previous estimate of 5-8%. For fiscal 2008, the company recorded revenues of $9.9bn, up 11% compared to 2007. This sales growth was helped by a 12% gain in revenue from the firm’s medical device business, which contributed around $6.8bn. The increase in sales had a positive affect on Covidien’s bottom line – the company posted net income of approximately $1.4bn, a marked improvement on the loss of $342m in fiscal 2007.
You may also be interested in...
Alere aided by professional diagnostics sales in fourth quarter
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra and Stout to work on expandable interbody device
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals